Thorsten Derlin1, Rudolf A Werner2, Marcel Lafos3, Christoph Henkenberens4, Christoph A J von Klot5, Jan M Sommerlath Sohns2, Tobias L Ross2, Frank M Bengel2. 1. Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany derlin.thorsten@mh-hannover.de. 2. Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany. 3. Institute of Pathology, Hannover Medical School, Hannover, Germany. 4. Department of Radiotherapy and Special Oncology, Hannover Medical School, Hannover, Germany; and. 5. Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.
Abstract
Neuroendocrine differentiation is associated with treatment failure and poor outcome in metastatic castration-resistant prostate cancer. We investigated the effect of circulating neuroendocrine biomarkers on the efficacy of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT). Methods: Neuroendocrine biomarker profiles (progastrin-releasing peptide, neuron-specific enolase, and chromogranin-A) were analyzed in 50 patients commencing 177Lu-PSMA-617 RLT. The primary endpoint was a prostate-specific antigen response in relation to baseline neuroendocrine marker profiles. An additional endpoint was progression-free survival. Tumor uptake on posttherapeutic scans, a known predictive marker for response, was used as a control variable. Results: Neuroendocrine biomarker profiles were abnormal in most patients. Neuroendocrine biomarker levels did not predict treatment failure or early progression (P ≥ 0.13). By contrast, intense PSMA-ligand uptake in metastases predicted both treatment response (P = 0.0030) and reduced risk of early progression (P = 0.0111). Conclusion: Neuroendocrine marker profiles do not predict an adverse outcome from RLT. By contrast, high ligand uptake was confirmed to be crucial for achieving a tumor response.
Neuroendocrine differentiation is associated with treatment failure and poor outcome in metastatic castration-resistant prostate cancer. We investigated the effect of circulating neuroendocrine biomarkers on the efficacy of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT). Methods: Neuroendocrine biomarker profiles (progastrin-releasing peptide, neuron-specific enolase, and chromogranin-A) were analyzed in 50 patients commencing 177Lu-PSMA-617 RLT. The primary endpoint was a prostate-specific antigen response in relation to baseline neuroendocrine marker profiles. An additional endpoint was progression-free survival. Tumor uptake on posttherapeutic scans, a known predictive marker for response, was used as a control variable. Results: Neuroendocrine biomarker profiles were abnormal in most patients. Neuroendocrine biomarker levels did not predict treatment failure or early progression (P ≥ 0.13). By contrast, intense PSMA-ligand uptake in metastases predicted both treatment response (P = 0.0030) and reduced risk of early progression (P = 0.0111). Conclusion: Neuroendocrine marker profiles do not predict an adverse outcome from RLT. By contrast, high ligand uptake was confirmed to be crucial for achieving a tumor response.
Authors: Kerstin Michalski; Claudius Klein; Tonio Brueggemann; Philipp T Meyer; Cordula Annette Jilg; Juri Ruf Journal: J Nucl Med Date: 2021-03-31 Impact factor: 11.082
Authors: Mohammad S Sadaghiani; Sara Sheikhbahaei; Rudolf A Werner; Kenneth J Pienta; Martin G Pomper; Michael A Gorin; Lilja B Solnes; Steven P Rowe Journal: Prostate Date: 2022-03-14 Impact factor: 4.012
Authors: Marco Bergamini; Alberto Dalla Volta; Irene Caramella; Luisa Bercich; Simona Fisogni; Mattia Bertoli; Francesca Valcamonico; Salvatore Grisanti; Pietro Luigi Poliani; Francesco Bertagna; Alfredo Berruti Journal: Front Oncol Date: 2022-07-22 Impact factor: 5.738
Authors: Martin K Bakht; John J Hayward; Farsheed Shahbazi-Raz; Magdalena Skubal; Ryo Tamura; Keith F Stringer; Daniel Meister; Varadha Balaji Venkadakrishnan; Hui Xue; Adam Pillon; Mathew Stover; Adam Tronchin; Bre-Anne Fifield; Lavleen Mader; Sheng-Yu Ku; Gi Jeong Cheon; Keon Wook Kang; Yuzhuo Wang; Xuesen Dong; Himisha Beltran; Jan Grimm; Lisa A Porter; John F Trant Journal: Proc Natl Acad Sci U S A Date: 2022-01-25 Impact factor: 12.779
Authors: Liam Widjaja; Rudolf A Werner; Tobias L Ross; Frank M Bengel; Thorsten Derlin Journal: Eur J Nucl Med Mol Imaging Date: 2021-05-27 Impact factor: 9.236